Cancer Segment Bolsters Predictive Genetic Testing Market Growth

According to our new research study on "Predictive Genetic Testing Market Forecast to 2031 - Global Analysis - by Type, Disease, and End User", the market was valued at US$1,421.39 million in 2024 and is projected to reach US$4,205.43 million by 2031; it is estimated to register a CAGR of 17.1% during 2025-2031. The predictive genetic testing market report highlights the prevailing trends in the global market, as well as the drivers and deterrents influencing its growth.

The predictive genetic testing marketplace is rapidly changing, in large part because the need for early identification of hereditary disease risks and personalized healthcare strategies is increasing. Currently, next-generation sequencing, bioinformatics, and cost-effective testing technologies are significantly contributing to the accessibility and clinical value of predictive screening. Patient awareness of heritable diseases, genetic disorders, and the application of genetic insights in everyday medical decision-making are the primary factors driving market growth. Healthcare systems, hospitals, and diagnostic laboratories are increasingly implementing predictive tests to facilitate preventive care, targeted therapies, and long-term disease management. In addition, regulatory measures that support the market and the development of genetic counseling services pave the way for growth in all global regions.

Surging Preference for Direct-To-Consumer (DTC) Genetic Testing Bolsters Predictive genetic testing Market Growth

Predictive genetic testing and screening have long been utilized to help individuals and families understand their inherited risk for various diseases. Traditionally, such testing has been conducted through genetic counselors, who determine the appropriate test, order it from a certified laboratory, collect and submit DNA samples, interpret the results, and communicate findings to patients. Hence, predictive genetic tests have been performed and analyzed in clinical or research settings. However, in recent years, direct-to-consumer (DTC) predictive genetic testing has gained remarkable traction and is becoming increasingly mainstream.

Leading industry players are expanding their portfolios to include DTC predictive genetic tests, supported by strategic marketing campaigns that enhance product visibility. In April 2017, the U.S. FDA authorized 23andMe to market DNA tests assessing the user's risk for ten health conditions, including late-onset Alzheimer's and Parkinson's disease-the first FDA-approved DTC tests of their kind. The increasing availability of predictive DTC testing and the rising consumer focus on proactive health management are key factors driving the expansion of the predictive genetic testing market.

The predictive genetic testing market analysis has been conducted by considering the following segments: type, disease, end user, and geography. In terms of type, the predictive genetic testing market is segmented into predispositional testing and presymptomatic testing. The predispositional testing segment held a larger market share in 2024.

Based on disease, the predictive genetic testing market is segmented into cancer, cardiovascular diseases, metabolic diseases, and other diseases. The cancer segment accounted for the largest share of the predictive genetic testing market in 2024. Predictive genetic testing locates mutations that are passed down from the parents and increase the risk of cancer. In this way, methods for early detection, prevention, and personalized treatment become available.

In terms of end user, the predictive genetic testing market is segmented into hospital-based laboratories, diagnostic laboratories, and other end users. The hospital-based laboratories segment held a larger market share in 2024. Hospital-based laboratories are growing due to integrated genetic workflows, the expansion of precision medicine, the adoption of advanced sequencing, clinician collaboration, rising awareness, and an increasing demand for early hereditary risk detection.

The geographic scope of the predictive genetic testing market report includes assessing the market performance in North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. North America is expected to dominate the market in 2024. The predictive genetic testing market in North America is segmented into the US, Canada, and Mexico. In the US, predictive genetic testing is deeply integrated into consumer wellness and clinical healthcare. The nation leads globally, driven by large genomics companies such as 23andMe, Myriad Genetics, and Invitae. The Genetic Information Non-discrimination Act (GINA) helps protect individuals from discrimination based on genetic risk in health insurance and employment, encouraging use of predictive testing. However, consumer genetic testing remains under scrutiny. In 2025, over two dozen states filed a lawsuit against 23andMe over its plan to sell customer genetic data amid its bankruptcy proceedings, highlighting data privacy concerns. Meanwhile, the adoption of predictive tests in clinical settings is rising, particularly for cancer risk panels and multigene tests, supported by FDA-authorized offerings and growing physician acceptance. Despite challenges around data privacy and business model sustainability, the US remains the most influential market for predictive genetic testing.

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com